Abstract
Objective: Low-carbohydrate diets should be avoided in patients receiving Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors to reduce the risk of Diabetic Ketoacidosis (DKA). High-dose acarbose has been reported to delay and reduce the absorption of carbohydrates.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have